Icahn Unveils Tender Offer For Vivus’ Debt
Carl Icahn’s Icahn Enterprises through its subsidiary IEH Biopharma LLC unveiled a tender offer on Wednesday to buy up all of Vivus’ convertible notes at a price of $680 for each $1,000 note.
Reacting favorably to the announcement, obesity company Vivus shares jumped 13% to $1.35 on Wednesday.
Icahn into biopharma again
IEH Biopharma LLC, a subsidiary of Icahn Enterprises L.P., announced on Wednesday a
![]() SORRY! This content is exclusively for paying members. If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.
|